Steve Alexy walked carefully and pigeon-toed toward the dumbbells and mirror at the back of the gym, one arm held tight ...
In mouse cerebellar slice cultures, blocking mGluR1 partially restored dendritic, spine and postsynaptic abnormalities in ...
Biohaven Ltd. BHVN stock is surging on Thursday with a session volume of 10.293 million versus an average volume of 2.585 ...
Investor's Business Daily on MSN
Why Biohaven catapulted 25% — and why it might not be done sprinting
Biohaven stock catapulted more than 30% early Thursday after the FDA said it would review the company's embattled drug, troriluzole.
Each person's kind heartAt the end of April 2025, I suddenly collapsed due to an unknown illness.I heard that afterward, I ...
Biohaven shares rose sharply in premarket trading Thursday after the clinical-stage biopharmaceutical company said the U.S. Food and Drug Administration has accepted its resubmitted application ...
A new study analyzing genetic data from the Quebec population indicates that several repeat expansion disorders (REDs) and ...
A population-based sequencing study estimates unusually high frequencies of several rare neurological disease variants in ...
Dublin, Oct. (GLOBE NEWSWIRE) -- "Spinocerebellar Ataxias - Pipeline Insight, 2026" has been added to ResearchAndMarkets.com's offering. The report provides a comprehensive analysis of the global ...
AMERICANS with 314 health conditions are able to get their Social Security checks delivered faster. The Social Security ...
Neurovascular studies in the Bonanomi laboratory are supported by European Research Council (ERC) Synergy Grant MINerVA no.
Biohaven's troriluzole candidate for spinocerebellar ataxia (SCA) has been turned down by the FDA, causing shares in the company to lose more than 40% of their value in pre-market trading. The news is ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results